ReviewGeriatrics (Basel, Switzerland)2016
Prostate Cancer: Is It a Battle Lost to Age?
Review in Geriatrics (Basel, Switzerland), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Quantitative digital pathology reveals morphological and molecular correlates of tumor aggressiveness in prostate cancer.International urology and nephrology · 2026Article
- Predictors of postoperative delirium in patients undergoing radical prostatectomy: a prospective study.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025Article
- Tissue immunostaining of candidate prognostic proteins in metastatic and non-metastatic prostate cancer.Journal of cancer research and clinical oncology · 2023Article
- A 4-Gene Signature of CDKN1, FDXR, SESN1 and PCNA Radiation Biomarkers for Prediction of Patient Radiosensitivity.International journal of molecular sciences · 2021Article
- Prostate Cancer-Focus on Cholesterol.Cancers · 2021Review
- A Novel Controlled PTEN-Knockout Mouse Model for Prostate Cancer Study.Frontiers in molecular biosciences · 2021Article
- Chimeric cytokine receptor enhancing PSMA-CAR-T cell-mediated prostate cancer regression.Cancer biology & therapy · 2020Article
- SNP-SNP interactions as risk factors for aggressive prostate cancer.F1000Research · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Age is often considered an important non-modifiable risk factor for a number of diseases, including prostate cancer. Some prominent risk factors of prostate cancer include familial history, ethnicity and age. In this review, various genetic and physiological characteristics affected due to advancing age will be analysed and correlated with their direct effect on prostate cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.